Home / Journals / CJU / Vol.28, No.1, 2021
Special Issues
  • Open AccessOpen Access

    EDITORIAL

    The Assault on Science and ………Urology

    Kevin R. Loughlin
    Canadian Journal of Urology, Vol.28, No.1, pp. 10500-10501, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LEGENDS IN UROLOGY

    LEGENDS IN UROLOGY

    Raja B. Khauli
    Canadian Journal of Urology, Vol.28, No.1, pp. 10502-10505, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LETTER

    Re: Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol 2020;27(3):10213-10219

    Adel Arezki1,*, Iman Sadri1,*, Ahmed S. Zakaria2, David-Dan Nguyen1, Naeem Bhojani2, Dean Elterman3, Bilal Chughtai4, Kevin C. Zorn2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10506-10507, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    LETTER

    Re: Tutrone R, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol 2020;27(3):10213-10219.

    Ronald F. Tutrone1, William Schiff2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10508-10509, 2021
    Abstract This article has no abstract. More >

  • Open AccessOpen Access

    REVIEW

    Ureteroscopic evaluation and treatment of benign essential hematuria: a systematic review

    Nicholas N. Tadros1, Michael J. Conlin2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10510-10515, 2021
    Abstract Introduction: The advent of ureteroscopy has revolutionized the treatment many urologic diseases, including benign essential hematuria. This systematic review examines the treatment of benign essential hematuria (BEH) with ureteroscopic interventions.
    Materials and methods: We performed a systematic review of the literature from 1977 to May 2020. We included studies that evaluated the use of ureteroscopy to diagnose or treat BEH. Demographics, follow up, findings, treatment method and success rate were extracted from each identified paper. Quality analysis was performed independently by both authors.
    Results: Our search resulted in 587 articles. Fifteen of these studies met inclusion criteria and… More >

  • Open AccessOpen Access

    ARTICLE

    Stent duration and increased pain in the hours after ureteral stent removal

    Michael E. Rezaee1, Annah J. Vollstedt1, Tammer Yamany2, Manoj Monga3,4, Amy Krambeck4,5, Ojas Shah4,6, Roger L. Sur3,4, Anna M. Zampini4,7, Kymora B. Scotland4,8, Ben H. Chew4,8, Brian H. Eisner2,4, Vernon M. Pais Jr1,4
    Canadian Journal of Urology, Vol.28, No.1, pp. 10516-10521, 2021
    Abstract Introduction: To assess the relationship between pain after ureteral stent removal and patient and procedural factors.
    Materials and methods: A validated survey designed to assess the relationship between quality of life and treatment decisions in kidney stone disease was randomly distributed to patients with a history of a ureteral stent in seven medical centers across North America participating in an endourology research collaborative between July 2016 and June 2018. The primary outcome was increased pain after ureteral stent removal. Statistical analyses were performed using Chi-square and multiple logistic regression.
    Results: A total of 327 surveys were analyzed. Twenty… More >

  • Open AccessOpen Access

    ARTICLE

    Primary malignancies of the epididymis: clinical characteristics and prognostic factors

    Hriday P. Bhambhvani1, Daniel R. Greenberg1, Alex M. Kasman1, Michael L. Eisenberg1
    Canadian Journal of Urology, Vol.28, No.1, pp. 10522-10529, 2021
    Abstract Introduction: We sought to describe clinical characteristics and identify prognostic factors among patients with primary malignancies of the epididymis (PMEs).
    Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) database (1975-2015) was queried to identify patients with PME. Descriptive statistics and multivariable Cox proportional hazards models were used.
    Results: Eighty-nine patients with PME were identified. Median age was 57 years (5-85), and median overall survival (OS) was 16.8 years. The most commonly represented histologies were rhabdomyosarcoma (19.1%), B-cell lymphoma (16.9%), leiomyosarcoma (16.9%), and liposarcoma (12.4%). In multivariable analysis, tumor size ≥ 4 cm was associated with worse… More >

  • Open AccessOpen Access

    Second opinion pathologic review in the management of prostate cancer

    Bofeng Chen1, Ruchika Talwar1, Lauren E. Schwartz2, Ryan P. Terlecki3, Thomas J. Guzzo1, Robert C. Kovell1
    Canadian Journal of Urology, Vol.28, No.1, pp. 10530-10535, 2021
    Abstract Introduction: Inter-institutional re-review of prostate needle biopsy (PNBx) material is required at many institutions before definitive treatment, but adds time and cost and may not significantly alter urologic management. We aim to determine the utility of universal PNBx re-review on influencing the decision to recommend definitive local therapy for patients with prostate cancer.
    Materials and methods: From 2017-2020, 590 prostate biopsy specimens from outside institutions were re-reviewed at our center for patients considering prostatectomy. Clinical and pathologic characteristics from initial and secondary review were analyzed. Potential for change in treatment candidacy (CTC) was determined by re-diagnosis to… More >

  • Open AccessOpen Access

    ARTICLE

    Do patients with ureterolithiasis treated conservatively return to follow up?

    Jonathan Modai1, Noam Barda2, Yuval Avda1, Igal Shpunt1, Dan Leibovici1, Yaniv Shilo1
    Canadian Journal of Urology, Vol.28, No.1, pp. 10536-10541, 2021
    Abstract Introduction: Distal ureteral stones (DUS) are common in patients presenting to the emergency department (ED) with renal colic. The majority of DUS will pass spontaneously and therefore conservative care is common. Follow up is imperative as some of these stones might not pass and potentially lead to complications. The aim of our study was to evaluate the rate of compliance with follow up and to find predictive variables for it.
    Materials and methods: We retrospectively surveyed the medical records of all patients who had a non-contrast computed tomography (NCCT) at our ED between 01/03/16 and 31/5/17. We… More >

  • Open AccessOpen Access

    ARTICLE

    Use of prescription drug monitoring program to audit opioid prescribing patterns for patients with symptomatic nephrolithiasis

    Rahima Khatun1, Matthew Galida2, Necole M. Streeper2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10542-10546, 2021
    Abstract Introduction: The opioid epidemic is a growing problem in the United States. There is a high rate of opioid oversupply for treatment of symptomatic nephrolithiasis, partly due to patients being seen by multiple providers. In Pennsylvania, there are efforts to integrate a prescription drug monitoring program (PDMP) within the electronic medical record (EMR). The objectives of this study were to evaluate prescribing practices for opioids for symptomatic nephrolithiasis and the incidence of prescriptions not documented within the EMR.
    Materials and methods: Adults who presented for treatment of symptomatic nephrolithiasis were sequentially evaluated from May - October 2017… More >

  • Open AccessOpen Access

    ARTICLE

    Race as a predictor of pathologic response to neoadjuvant chemotherapy at time of cystectomy for bladder cancer

    Ankur Choksi1, Shu Wang1, Michael Phelan1, Heather Mannuel2, Michael Naslund1, Mohummad Minhaj Siddiqui1
    Canadian Journal of Urology, Vol.28, No.1, pp. 10547-10555, 2021
    Abstract Introduction: Complete pathologic response (pT0) at time of cystectomy after neoadjuvant chemotherapy (NAC) has been associated with significantly improved clinical outcomes. The goal of this study is to examine whether race is a predictor of pT0 response to NAC at time of cystectomy.
    Materials and methods: We analyzed the records of patients diagnosed with a non-metastatic (M0) muscle-invasive (cT2+) urothelial cell bladder cancer in the National Cancer Database (NCDB) who underwent a cystectomy from 2006 to 2014. The cohort was stratified by whether the patient received NAC prior to cystectomy. Univariate and multivariate logistic regression models were… More >

  • Open AccessOpen Access

    RESIDENT’S CORNER

    Celiac plexus block for chronic flank pain: a case series

    William W. French1, Joseph M. Kuebker2, Xiang Shu3, Christopher M. Sobey4, Ryan S. Hsi2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10556-10559, 2021
    Abstract Non-obstructive, chronic flank pain in urologic patients can be a challenging problem to manage. In this series, we examined the efficacy of celiac plexus blockade in providing pain relief and reducing opiate use in 14 adult urology patients with non-obstructive flank pain for > 1 year. Demographic, clinical, and procedural variables were collected from the medical record for retrospective analysis. Subjective improvement in pain occurred in 11 individuals (79%), and 5 (50%) were able to reduce their daily morphine equivalent dose (MED). Celiac plexus blockade is a viable option for symptomatic relief in urologic patients More >

  • Open AccessOpen Access

    RESIDENT’S CORNER

    Pyoderma gangrenosum of the penis

    Justin Loloi1, Susan M. MacDonald2
    Canadian Journal of Urology, Vol.28, No.1, pp. 10560-10564, 2021
    Abstract Pyodermagangrenosum(PG)isacutaneousinfammatory disorderthatresultsinpainfululcers. IsolatedpenilePG is an exceedingly rare entity that has only been reported in a handful of cases.
    This case highlights the course of a 71-year old man with a locally destructive, nonhealing penile ulceration who was ultimately diagnosed with PG. He underwent extensive work up to reach the diagnosis. His disease progression was halted with systemic steroids and Methotrexate.Wepresenthisclinicalcourseandareview oftheliteraturetohighlighttheneedforearlyrecognition of this potentially devastating condition and to outline management options. More >

  • Open AccessOpen Access

    RESIDENT’S CORNER

    Solitary brain metastasis after recurrent adenocarcinoma of the prostate

    Miguel Rodriguez-Homs1, Brett Wiesen1, Mona Rizeq2, Colin Randau3, Granville L. Lloyd4
    Canadian Journal of Urology, Vol.28, No.1, pp. 10565-10567, 2021
    Abstract Prostate cancer is rarely metastatic to visceral organs, and even less commonly to the brain. Recent data suggests brain metastasis from prostatic adenocarcinoma occur in 0.16% of patients, and almost universally in the setting of very high-volume disease. We present a man with an abruptly symptomatic brain lesion that developed at a PSA value of 1.5 ng/mL with no other known metastatic disease and required emergent neurosurgical resection. The patient had been initially treated with radiotherapy for Grade Group 4 prostate cancer in 2005 with a long period of PSA suppression. More >

  • Open AccessOpen Access

    HOW I DO IT

    DNA analysis for prostate specimen verification: How I Do It

    Andrew Salib, J. Ryan Mark
    Canadian Journal of Urology, Vol.28, No.1, pp. 10568-10573, 2021
    Abstract Prostate cancer is the most common malignancy affecting men. Prostate biopsy remains the key clinical tool for selecting appropriate treatment options. The process of specimen collection and diagnosis is multistep and vulnerable to human error along every stage. Specimen provenance testing (SPT) aims to provide certainty that biopsy results can be trusted when recommending life changing treatments and has emerged as a necessary tool in medicine to counteract human error and specimen contamination. In this study we report our practice’s experience using the Know Error test to verify prostate biopsy specimens. In this study, we… More >

Per Page:

Share Link